Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 23, 2024
Reporting Period: The filing addresses a restatement of financial statements for the two years ended December 31, 2023, and the interim quarters from March 31, 2022, through September 30, 2023.
Key Financial Metrics
This filing does not report new revenue, profit, cash flow, or debt figures. It specifically addresses the classification of certain financial instruments.
- Cash Impact: The filing explicitly states that the adjustments are non-cash and do not impact previously reported amounts for cash, cash equivalents, or investments in marketable securities.
- Income Statement Impact: The adjustments will not impact previously reported revenues, operating expenses, or loss from operations.
- Balance Sheet Impact: Warrants previously classified as stockholders' equity must be reclassified as liabilities.
Material Changes Versus Prior Period
The Company concluded that previously issued financial statements for the "Affected Periods" should be restated due to a misapplication of accounting guidance regarding warrants issued in November 2021. The material changes include:
- Reclassification: Warrants to purchase an aggregate of 4,737,908 shares (comprising Public Warrants, Private Warrants, and Underwriter Warrants) must be moved from stockholders' equity to liabilities on the balance sheet.
- Valuation Adjustments: Future statements of operations must include non-cash changes in the estimated fair value of these warrants.
- Scope: The restatement covers the Annual Report on Form 10-K for 2023 and interim reports for Q1, Q2, and Q3 of 2023.
Guidance, Outlook, and Management Commentary
Management Action Plan:
- The Company anticipates filing an amended Annual Report on Form 10-K for the year ended December 31, 2023, reflecting the restatement.
- Target Filing Date: On or before June 28, 2024.
- Concurrent Filing: The Quarterly Report on Form 10-Q for the period ended March 31, 2024, will be filed concurrently with the amended 10-K.
- Interim Periods: The Company does not intend to amend previously issued Form 10-Qs for the interim periods; instead, the impact will be summarized in the amended 10-K and effectuated in future 2024 10-Q filings.
Risks and Contingencies: The preliminary evaluation is subject to the completion of the restatement analysis, financial close, and audits/reviews by the independent registered accounting firm, Marcum LLP.
Investor Verification Checklist
- Verify the specific liability amounts and fair value adjustments once the Amended Form 10-K is filed by June 28, 2024.
- Confirm that the reclassification of warrants does not trigger any debt covenants or liquidity restrictions.
- Monitor the upcoming Q1 2024 Form 10-Q for the initial presentation of the restated financial data.
- Review the Audit Committee's communication with Marcum LLP regarding the scope of the restatement.